prilocaine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
local anaesthetics	2265	721-50-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: propitocaine hydrochloride prilocaine propitocaine (+/-)-Prilocaine prilocaine hydrochloride propitocaine HCl prilocaine HCl	A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry. Molecular weight: 220.32 Formula: C13H20N2O CLOGP: 1.81 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 41.13 ALOGS: -2.83 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

propitocaine hydrochloride
prilocaine
propitocaine
(+/-)-Prilocaine
prilocaine hydrochloride
propitocaine HCl
prilocaine HCl

A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.

Molecular weight: 220.32
Formula: C13H20N2O
CLOGP: 1.81
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 41.13
ALOGS: -2.83
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	33.51 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	3.70 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	29 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.72 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 18, 1965	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic reaction	146.53	25.78	52	1096	66048	63421826
Necrotising fasciitis	58.18	25.78	13	1135	3028	63484846
Drug intolerance	55.20	25.78	45	1103	308616	63179258
XIIth nerve injury	44.84	25.78	5	1143	8	63487866
Methaemoglobinaemia	28.64	25.78	7	1141	2396	63485478

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Electrocardiogram QRS complex prolonged	86.56	35.53	18	378	4876	34951659
Cardiotoxicity	51.05	35.53	12	384	5636	34950899
Coma	46.80	35.53	18	378	45660	34910875
Respiratory failure	46.20	35.53	23	373	108549	34847986
Overdose	37.80	35.53	19	377	91040	34865495

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic reaction	142.80	25.55	52	1171	83691	79659474
Drug intolerance	68.10	25.55	45	1178	264074	79479091
Electrocardiogram QRS complex prolonged	66.63	25.55	18	1205	10815	79732350
Necrotising fasciitis	51.41	25.55	13	1210	6037	79737128
XIIth nerve injury	45.66	25.55	5	1218	8	79743157
Cardiotoxicity	38.14	25.55	12	1211	12227	79730938
Respiratory failure	32.94	25.55	25	1198	180886	79562279
Coma	32.92	25.55	20	1203	100629	79642536

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N01BB04	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, LOCAL Amides
ATC	N01BB54	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, LOCAL Amides
FDA CS	M0000897	Amides
MeSH PA	D000777	Anesthetics
MeSH PA	D000779	Anesthetics, Local
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35623	anticonvulsants
CHEBI has role	CHEBI:36333	local anesthetics
FDA EPC	N0000175682	Amide Local Anesthetic
FDA PE	N0000175976	Local Anesthesia

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Premature ejaculation	indication	44001008	DOID:13709
Local anesthesia	indication	386761002
Bacterial septicemia	contraindication	10001005	DOID:0040085
Sinus tachycardia	contraindication	11092001
Myocardial infarction	contraindication	22298006	DOID:5844
Shock	contraindication	27942005
Parkinsonism	contraindication	32798002
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Cerebral arteriosclerosis	contraindication	65312002
Diabetes mellitus	contraindication	73211009	DOID:9351
Decreased respiratory function	contraindication	80954004
Cardiogenic shock	contraindication	89138009
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Open wound	contraindication	125643001
Seizure disorder	contraindication	128613002
Bleeding	contraindication	131148009
Angina pectoris	contraindication	194828000
Primary dilated cardiomyopathy	contraindication	195021004
Heart block	contraindication	233916004
Disease of liver	contraindication	235856003	DOID:409
Deficiency of cholinesterase	contraindication	360607009
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Disorder of coronary artery	contraindication	414024009
Denuded skin	contraindication	418242004

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.81	acidic
pKa2	8.13	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN	BLOCKER	IC50	4.27		CHEMBL	CHEMBL

External reference:

ID	Source
4018911	VUID
N0000178903	NUI
D00553	KEGG_DRUG
1786-81-8	SECONDARY_CAS_RN
4018911	VANDF
4019902	VANDF
C0033124	UMLSCUI
CHEBI:32053	CHEBI
CHEMBL1194	ChEMBL_ID
DB00750	DRUGBANK_ID
CHEMBL1200586	ChEMBL_ID
D011318	MESH_DESCRIPTOR_UI
4906	PUBCHEM_CID
7276	IUPHAR_LIGAND_ID
1641	INN_ID
046O35D44R	UNII
2557	RXNORM
5352	MMSL
5353	MMSL
d01396	MMSL
001367	NDDF
004574	NDDF
19232009	SNOMEDCT_US
387107003	SNOMEDCT_US
387299004	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	0115-1468	CREAM	25 mg	TOPICAL	ANDA	20 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	0168-0357	CREAM	25 mg	TOPICAL	ANDA	25 sections
Prilocaine Hydrochloride with Epinephrine	HUMAN PRESCRIPTION DRUG LABEL	2	0362-9013	INJECTION, SOLUTION	40 mg	SUBCUTANEOUS	ANDA	24 sections
Prilocaine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0362-9014	INJECTION, SOLUTION	40 mg	SUBCUTANEOUS	ANDA	24 sections
LIDOCAINE AND PRILOCAINE	HUMAN PRESCRIPTION DRUG LABEL	2	0574-2042	CREAM	25 mg	TOPICAL	ANDA	21 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	0591-2070	CREAM	25 mg	TOPICAL	NDA authorized generic	24 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	0591-2070	CREAM	25 mg	TOPICAL	NDA authorized generic	24 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	0591-2070	CREAM	25 mg	TOPICAL	NDA authorized generic	24 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	0904-6989	CREAM	25 mg	TOPICAL	ANDA	27 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	21695-388	CREAM	25 mg	TOPICAL	ANDA	25 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	33261-591	CREAM	25 mg	TOPICAL	ANDA	21 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	42254-195	CREAM	25 mg	TOPICAL	ANDA	21 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	42858-029	CREAM	25 mg	TOPICAL	ANDA	26 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	42858-029	CREAM	25 mg	TOPICAL	ANDA	26 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	50090-2167	CREAM	25 mg	TOPICAL	ANDA	20 sections
LIDOCAINE AND PRILOCAINE	HUMAN PRESCRIPTION DRUG LABEL	2	50090-6589	CREAM	25 mg	TOPICAL	ANDA	21 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	50383-667	CREAM	25 mg	TOPICAL	ANDA	21 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	50383-667	CREAM	25 mg	TOPICAL	ANDA	21 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	52565-007	CREAM	25 mg	TOPICAL	ANDA	27 sections
LIDOCAINE AND PRILOCAINE	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5194	CREAM	25 mg	TOPICAL	ANDA	25 sections
LIDOCAINE AND PRILOCAINE	HUMAN PRESCRIPTION DRUG LABEL	2	61919-443	CREAM	25 mg	TOPICAL	NDA	13 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	62332-582	CREAM	25 mg	TOPICAL	ANDA	13 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	62332-582	CREAM	25 mg	TOPICAL	ANDA	13 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	62332-582	CREAM	25 mg	TOPICAL	ANDA	13 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	63187-577	CREAM	25 mg	TOPICAL	NDA authorized generic	24 sections
LIDOCAINE AND PRILOCAINE	HUMAN PRESCRIPTION DRUG LABEL	2	63629-9604	CREAM	25 mg	TOPICAL	ANDA	21 sections
Lidocaine and Prilocaine	HUMAN PRESCRIPTION DRUG LABEL	2	63739-054	CREAM	25 mg	TOPICAL	ANDA	17 sections
Oraqix	HUMAN PRESCRIPTION DRUG LABEL	2	66312-110	GEL	25 mg	PERIODONTAL	NDA	27 sections
Citanest Forte	HUMAN PRESCRIPTION DRUG LABEL	2	66312-540	INJECTION, SOLUTION	40 mg	SUBMUCOSAL	NDA	24 sections
Citanest Forte DENTAL	HUMAN PRESCRIPTION DRUG LABEL	2	66312-580	INJECTION, SOLUTION	40 mg	PARENTERAL	ANDA	24 sections